Multi-centre in-human study of SKF7™ is the first clinical trial of its kind to be conducted in Malaysia, India and Indonesia

Written by Medika Natura

Formerly known as Orchid Life, Medika Natura is a pioneer in the end-to-end development, production and commercializing of botanical bio-active compounds native to Southeast Asia.

18 January 2021

A Phase 2 clinical trial of SK7™ is the first ever study of its kind to be launched in clinics and hospitals across Malaysia, India and Indonesia.

Medika Natura has initiated Phase 2 clinical trials of its proprietary bio-extract SKF7™ in general hospitals and clinics across Malaysia, Indonesia and India. The first clinical trial of its kind for all three countries, these randomized double-blind placebo-controlled studies are aimed at determining SKF7™ efficacy in curtailing obesity in order for it to be classified and marketed as an anti-obesity botanical drug.

A multinational, multi-centered study, this Phase 2 clinical trial was conducted in India in November 2020 and will soon be run in multiple healthcare facilities in Indonesia and Malaysia in March 2021 and June 2021, respectively.

Other News & Updates